RxDoctor Payments Data

Alexis Boro, MD

Neurology · Bronx, NYNPI 1457436131

Payments from drug & device makers

$401,096in general payments, 2019–2025

Across 110 payments — averaging $3646.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$144K
  • UCB SA$128K
  • SK Life Science, Inc.$127K
  • Neuropace, Inc.$1K
  • Livanova USA, Inc.$36

What the payments were for

  • Travel & lodging$2,00278%
  • Food & beverage$54922%

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen3$144,220
UCB SA31$128,282
SK Life Science, Inc.70$127,212
Neuropace, Inc.4$1,346
Livanova USA, Inc.2$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$401,096 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$18,757
Medicare patients
99
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate140$236,077
BriviactBrivaracetam63$88,484
EpidiolexCannabidiol (Cbd)13$54,723
AptiomEslicarbazepine Acetate16$35,938
KeppraLevetiracetam15$28,439
FycompaPerampanel19$20,567
Lacosamide191$18,299
Clobazam101$17,130
VimpatLacosamide15$17,009
ValtocoDiazepam11$8,718
Lamotrigine ErLamotrigine15$8,253
Carbamazepine ErCarbamazepine118$7,747
Topiramate21$7,678
Levetiracetam266$7,377
KlonopinClonazepam11$3,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$127,212$236,077140 claims
UCB SAKeppra$128,282$28,43915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →